Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
- 189 Downloads
Sustained virological response (SVR) rates in patients with hepatitis C are heterogeneous and are influenced by a wide range of host and viral factors.
To evaluate the efficacy of combination therapy with pegylated interferon alfa (PEG-IFN-α) and ribavirin (RBV), and document the SVR rates taking into consideration various predictive factors in patients with chronic hepatitis C (CHC) genotype 3.
Ninety-seven treatment-naive patients with CHC genotype 3 (mean age 41.46 ± 11.51 years, M:F ratio 79:18), who received a combination of PEG-IFN (α-2a or α-2b) and RBV were retrospectively analyzed (2006–2008) for the early virological response (EVR) at 12 weeks, end of treatment response (ETR), and SVR at 6 months.
Eighty-four (86.6%) patients achieved EVR and 81 (83.5%) achieved ETR, while SVR was achieved in 65 (67.0%) patients. Of the 84 patients who achieved EVR, 77 (91.7%) achieved ETR and 61 (72.6%) achieved SVR at 6 months. Age and body mass index (BMI) were found to be important predictors (*P < 0.05) of SVR. CHC patients with a history of alcohol intake showed decreased SVR (52%) (*P = 0.035) as compared to nonalcoholics (80%). Cirrhotic versus noncirrhotic patients showed no difference in SVR (54.5% vs. 70.7%) (P = 0.157). Serum alanine aminotransferase (ALT) (P = 0.169) and hepatitis C virus (HCV) RNA levels (P = 0.42) also did not have an influence on the SVR.
Combination therapy with PEG-IFN-α and RBV demonstrated good tolerability in CHC genotype 3 infection. Age, BMI, and alcohol consumption play an important role in determining treatment outcome.
KeywordsHCV genotype 3 Response to therapy Sustained virological response Pegylated interferon α + ribavirin
- 2.Pal SK, Chalamalasetty BS, Choudhuri G. Hepatitis C: a major health problem of India. Curr Sci. 2002;83:1058–1059.Google Scholar
- 8.National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology. 2002;36:S3–S20.Google Scholar
- 12.Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;4:1050–1056.CrossRefGoogle Scholar
- 14.Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–1432.PubMedCrossRefGoogle Scholar
- 33.Pattullo V, Ravindran NC, Mazzulli T, et al. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. J Viral Hepat. 2010;17:834–838.PubMedCrossRefGoogle Scholar